Daratumumab-Based Frontline Therapy in Newly Diagnosed Multiple Myeloma

Dr. Ajai Chari and NP Samantha Shenoy discuss the clinical rationale for incorporating daratumumab-based regimens into the frontline management of newly diagnosed multiple myeloma (NDMM). The conversation explores the biologic rationale for targeting CD38 and reviews how daratumumab-based combinations have contributed to deeper responses and improved minimal residual disease (MRD) negativity in clinical studies. The faculty discuss patient selection in transplant-ineligible disease, emphasizing the importance of balancing efficacy with tolerability, comorbidities, and long-term treatment goals. Dr. Chari and NP Shenoy also share their perspectives on how CD38-directed therapy has influenced frontline treatment strategies and discuss practical considerations when selecting regimens for older or medically complex patients. The discussion provides important clinical context for understanding the evidence supporting daratumumab-based approaches and their role in optimizing outcomes for patients with NDMM.